ZHIFEI-BIOL announced that its operating revenue in the first half of 2025 was 4.919 billion yuan, a year-on-year decrease of 73.06%. The net profit loss was 597 million yuan, compared to a net profit of 2.234 billion yuan in the same period last year. During the reporting period, affected by multiple factors such as the decline in public vaccination willingness and changes in market demand, the company reached an agreement with Merck to adjust the procurement and supply rhythm of HPV vaccines for this year, and continued to conduct demand assessments to jointly respond to market changes